Scilex (SCLX) announced that it will be filing today of a Supplemental New Drug Application, SNDA, with the FDA for ELYXYB in acute pain indication. “We are well positioned to broaden the ELYXYB(R) label with an additional acute pain indication and further solidify the potential role of ELYXYB as a cornerstone in opioid-sparing acute pain management regimens that support accelerated recovery and eventually freedom from pain”, said Dmitri Lissin, M.D., Chief Medical Officer of Scilex.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCLX:
- Scilex amends license agreement with Romeg Therapeutics
- Scilex announces Pain Medicine News published data on ZTildo vs Lidocaine 5%
- Scilex Adjusts Record Date for Preferred Stock Dividend
- Scilex announces change in record date for dividend of preferred stock
- Scilex Holding Co options imply 15.0% move in share price post-earnings